Related Experiment Video
Updated: Jul 20, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
The role of the epidermal growth factor receptor in breast cancer
Samuel K Chan1, Mark E Hill, William J Gullick
1Cancer Biology Laboratory, Research School of Biosciences, University of Kent, Canterbury, Kent CT2 7NJ, UK.
Abstract:
Recent trials of drug therapy targeting the erbB receptor HER2 have met with success in breast cancer. The epidermal growth factor receptor or EGFR is a closely related receptor from this same family that is involved in cellular signal transduction and tumor cell growth and survival. Emerging evidence indicates that EGFR is implicated in the development of hormone-resistant breast cancer, and that its activity is intertwined with estrogen receptor. Here, the role of EGFR in breast cancer is reviewed, and data from selected clinical trials of signal transduction inhibition of this cellular target are summarized.
Insights
Epidermal growth factor receptor (EGFR) shows promise in treating hormone-resistant breast cancer. Targeting EGFR may offer new therapeutic strategies for patients with this challenging condition.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Signaling
Background:
- HER2-targeted therapies show success in breast cancer treatment.
- Epidermal growth factor receptor (EGFR), a related erbB family member, influences tumor growth and survival.
- Emerging evidence links EGFR to hormone-resistant breast cancer and estrogen receptor activity.
Purpose of the Study:
- To review the role of EGFR in breast cancer development.
- To summarize clinical trial data on EGFR signal transduction inhibition.
Main Methods:
- Literature review of EGFR's role in breast cancer.
- Summary of clinical trial data for EGFR inhibitors.
Main Results:
- EGFR is involved in cellular signal transduction crucial for tumor growth.
- EGFR activity is interconnected with estrogen receptor pathways.
- Clinical trials investigate signal transduction inhibitors targeting EGFR.
Conclusions:
- EGFR is a significant factor in breast cancer progression, particularly hormone resistance.
- Targeting EGFR represents a potential therapeutic avenue for breast cancer.
- Further research and clinical trials are warranted for EGFR-targeted therapies.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Receptor Tyrosine Kinases
The Ras Gene
Ras is a superfamily...

